FDMT

4 D Molecular Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 0/10
  • Value↓ 0/10
4 D Molecular Therapeutics sales and earnings growth
FDMT Growth
Low
  • Revenue Y/Y↑ 347870.70%
  • EPS Y/Y↑ 19.18%
  • FCF Y/Y↑ 17.60%
4 D Molecular Therapeutics gross and profit margin trends
FDMT Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -182.30%
  • ROIC 5Y↓ -53.27%
4 D Molecular Therapeutics net debt vs free cash flow
FDMT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

4 D Molecular Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks